ArQule Shares Outstanding 2006-2018 | ARQL

ArQule shares outstanding from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ArQule Annual Shares Outstanding
(Millions of Shares)
2017 75
2016 70
2015 63
2014 63
2013 62
2012 60
2011 53
2010 45
2009 44
2008 44
2007 40
2006 36
2005 35
ArQule Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 107
Q2 2018 101
Q1 2018 87
Q4 2017 75
Q3 2017 72
Q2 2017 71
Q1 2017 71
Q4 2016 70
Q3 2016 71
Q2 2016 71
Q1 2016 65
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 63
Q1 2014 63
Q4 2013 62
Q3 2013 63
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 62
Q2 2012 61
Q1 2012 54
Q4 2011 53
Q3 2011 54
Q2 2011 53
Q1 2011 51
Q4 2010 45
Q3 2010 45
Q2 2010 45
Q1 2010 44
Q4 2009 44
Q3 2009 44
Q2 2009 44
Q1 2009 44
Q4 2008 44
Q3 2008 44
Q2 2008 44
Q1 2008 44
Q4 2007 40
Q3 2007 44
Q2 2007 37
Q1 2007 36
Q4 2006 36
Q3 2006 36
Q2 2006 35
Q1 2006 35
Q4 2005 35
Q3 2005 35
Q2 2005 35
Q1 2005 33
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.351B $0.005B
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Stock Name Country Market Cap PE Ratio
Shire (SHPG) Ireland $53.409B 11.39
Zoetis (ZTS) United States $42.496B 29.09
Grifols (GRFS) Spain $12.892B 15.73
Jazz Pharmaceuticals (JAZZ) Ireland $8.479B 12.17
Ionis Pharmaceuticals (IONS) United States $7.282B 0.00
Tilray (TLRY) United States $6.999B 0.00
Neurocrine Biosciences (NBIX) United States $6.469B 1426.80
Nektar Therapeutics (NKTR) United States $6.319B 9.06
Catalent (CTLT) United States $5.036B 21.12
Impax Laboratories (AMRX) United States $4.810B 0.00
Sage Therapeutics (SAGE) United States $4.782B 0.00
United Therapeutics (UTHR) United States $4.703B 7.69
Loxo Oncology (LOXO) United States $4.251B 0.00
TESARO (TSRO) United States $4.056B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.483B 12.90
FibroGen (FGEN) United States $3.361B 0.00
USANA Health Sciences (USNA) United States $2.895B 24.64
Endo (ENDP) Ireland $2.286B 3.50
Xencor (XNCR) United States $2.031B 0.00
Endocyte (ECYT) United States $1.957B 0.00
Heron Therapeutics (HRTX) United States $1.948B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.861B 251.44
Corcept Therapeutics (CORT) United States $1.860B 27.31
Ironwood Pharmaceuticals (IRWD) United States $1.810B 0.00
Zogenix (ZGNX) United States $1.739B 0.00
Aerie Pharmaceuticals (AERI) United States $1.737B 0.00
Madrigal Pharmaceuticals (MDGL) United States $1.697B 0.00
PTC Therapeutics (PTCT) United States $1.697B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.463B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.433B 20.15
Tricida (TCDA) United States $1.340B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.321B 0.00
Esperion Therapeutics (ESPR) United States $1.286B 0.00
Portola Pharmaceuticals (PTLA) United States $1.252B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.238B 0.00
TherapeuticsMD (TXMD) United States $0.921B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.906B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.807B 0.00
ImmunoGen (IMGN) United States $0.772B 0.00
Radius Health (RDUS) United States $0.719B 0.00
Forty Seven (FTSV) United States $0.712B 0.00
Collegium Pharmaceutical (COLL) United States $0.603B 0.00
Karyopharm Therapeutics (KPTI) United States $0.584B 0.00
Siga Technologies (SIGA) United States $0.558B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.513B 0.00
ChemoCentryx (CCXI) United States $0.507B 40.12
Flexion Therapeutics (FLXN) United States $0.505B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.455B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.446B 26.29
GlycoMimetics (GLYC) United States $0.446B 0.00
Akebia Therapeutics (AKBA) United States $0.435B 0.00
Xeris Pharmaceuticals (XERS) United States $0.420B 0.00
Dova Pharmaceuticals (DOVA) United States $0.418B 0.00
Dermira (DERM) United States $0.417B 0.00
Odonate Therapeutics (ODT) United States $0.406B 0.00
CASI Pharmaceuticals (CASI) United States $0.405B 0.00
Tyme Technologies (TYME) United States $0.398B 0.00
KalVista Pharmaceuticals (KALV) United States $0.390B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.373B 0.00
Translate Bio (TBIO) United States $0.370B 0.00
OptiNose (OPTN) United States $0.340B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.336B 0.00
Majesco Entertainment (PTE) United States $0.330B 0.00
Concert Pharmaceuticals (CNCE) United States $0.316B 0.00
Tapimmune (MRKR) United States $0.309B 0.00
Minerva Neurosciences (NERV) United States $0.305B 0.00
Aclaris Therapeutics (ACRS) United States $0.299B 0.00
Aratana Therapeutics (PETX) United States $0.299B 0.00
Mast Therapeutics (SVRA) United States $0.261B 0.00
Depomed (ASRT) United States $0.259B 9.64
Verrica Pharmaceuticals (VRCA) United States $0.258B 0.00
Aldeyra Therapeutics (ALDX) United States $0.248B 0.00
IMV INC (IMV) Canada $0.245B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.240B 0.00
Ocular Therapeutix (OCUL) United States $0.219B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.216B 0.00
Affimed (AFMD) Germany $0.213B 0.00
Galectin Therapeutics (GALT) United States $0.205B 0.00
Zafgen (ZFGN) United States $0.191B 0.00
Lannett Co Inc (LCI) United States $0.190B 1.65
TAIWAN LIPOSOME (TLC) Taiwan $0.188B 0.00
Aquestive Therapeutics (AQST) United States $0.184B 0.00
MEI Pharma (MEIP) United States $0.180B 0.00
Calithera Biosciences (CALA) United States $0.175B 0.00
Opexa Therapeutics (ACER) United States $0.174B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.172B 0.00
Molecular Templates (MTEM) United States $0.166B 0.00
ContraFect (CFRX) United States $0.165B 0.00
Recro Pharma (REPH) United States $0.164B 0.00
Nature's Sunshine Products (NATR) United States $0.162B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.159B 0.00
Neon Therapeutics (NTGN) United States $0.158B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.147B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.145B 0.00
Redhill Biopharma (RDHL) Israel $0.145B 0.00
Ardelyx (ARDX) United States $0.134B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.133B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.132B 0.00
MediWound (MDWD) Israel $0.130B 0.00
Cardiome Pharma (CORV) Canada $0.129B 0.00
ElectroCore (ECOR) United States $0.120B 0.00
Adherex Technologies (FENC) United States $0.117B 0.00
Jounce Therapeutics (JNCE) United States $0.115B 0.00
DURECT (DRRX) United States $0.112B 0.00
Champions Oncology (CSBR) United States $0.110B 0.00
ProNAi Therapeutics (SRRA) Canada $0.104B 0.00
Iterum Therapeutics (ITRM) Ireland $0.102B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.093B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.091B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.081B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.081B 0.00
Immune Design (IMDZ) United States $0.076B 0.00
Achaogen (AKAO) United States $0.075B 0.00
Natural Alternatives (NAII) United States $0.075B 7.36
CTI BioPharma (CTIC) United States $0.072B 0.00
Otonomy (OTIC) United States $0.070B 0.00
Infinity Pharmaceuticals (INFI) United States $0.069B 0.00
Nivalis Therapeutics (ALPN) United States $0.066B 0.00
Melinta Therapeutics (MLNT) United States $0.066B 0.00
BioLineRx (BLRX) Israel $0.066B 0.00
Neos Therapeutics (NEOS) United States $0.062B 0.00
KemPharm (KMPH) United States $0.062B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.058B 0.00
Avenue Therapeutics (ATXI) United States $0.056B 0.00
Genocea Biosciences (GNCA) United States $0.048B 0.00
Mannatechorporated (MTEX) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.042B 0.00
ProPhase Labs (PRPH) United States $0.036B 0.00
Capnia (SLNO) United States $0.035B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.034B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.033B 0.00
Novan (NOVN) United States $0.033B 0.00
Heat Biologics (HTBX) United States $0.030B 0.00
Lipocine (LPCN) United States $0.030B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.028B 0.00
Trillium Therapeutics (TRIL) Canada $0.027B 0.00
Xenetic Biosciences (XBIO) United States $0.024B 0.00
SCYNEXIS (SCYX) United States $0.024B 0.00
Biomerica (BMRA) United States $0.023B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.023B 0.00
Jaguar Animal Health (JAGX) United States $0.020B 0.00
HANCOCK JAFFE (HJLI) United States $0.020B 0.00
Cyanotech (CYAN) United States $0.020B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.020B 0.00
Citius Pharmaceuticals (CTXR) United States $0.020B 0.00
PharmAthene (ALT) United States $0.019B 0.00
Aviragen Therapeutics (VXRT) United States $0.018B 0.00
Onconova Therapeutics (ONTX) United States $0.018B 0.00
Pain Therapeutics (PTIE) United States $0.018B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.017B 6.05
ESSA Pharma (EPIX) Canada $0.016B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.014B 0.00
Shineco (TYHT) China $0.013B 1.40
Regulus Therapeutics (RGLS) United States $0.012B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.010B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.010B 0.00
Skyline Medical (AIPT) United States $0.010B 0.00
Apricus Biosciences (APRI) United States $0.008B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.007B 0.00
Aradigm (ARDM) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
Midatech Pharma (MTP) United Kingdom $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.005B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.004B 0.00
Bio Blast Pharma (ORPN) Israel $0.004B 0.00
Bio-Path Holdings (BPTH) United States $0.004B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.003B 0.00
Intellipharmaceutics (IPCI) Canada $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00